Long-term outcomes of measured and predicted prosthesis-patient mismatch following transcatheter aortic valve replacement

DOI: 10.4244/EIJ-D-23-00456

Daijiro Tomii
Daijiro Tomii1, MD; Taishi Okuno1, MD; Dik Heg2, PhD; Masaaki Nakase1, MD; Jonas Lanz1, MD, MSc; Fabien Praz1, MD; Stefan Stortecky1, MD, MPH; David Reineke3, MD; Stephan Windecker1, MD; Thomas Pilgrim1, MD, MSc
1. Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 2. CTU Bern, University of Bern, Bern, Switzerland; 3. Department of Cardiovascular Surgery, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland

Background: Both measured and predicted effective orifice area (EOA) indexed to the body surface area (EOAi) have been suggested to define prosthesis-patient mismatch (PPM) in patients undergoing transcatheter aortic valve replacement (TAVR). The impact of PPM on clinical outcomes may accumulate with extended follow-up and vary according to the definition used.

Aims: We aimed to investigate the long-term clinical impact of PPM in patients undergoing TAVR.

Methods: Patients in a prospective TAVR registry were stratified by the presence of moderate (0.65-0.85 or 0.55-0.70 cm2/m2 if obese) or severe (≤0.65 or ≤0.55 cm2/m2 if obese) PPM according to echocardiographically measured EOAi (measured PPM), predicted EOAi based on published EOA reference values for each valve model and size (predicted PPMTHV), or predicted EOAi based on EOA reference values derived from computed tomography measurements of aortic annulus dimensions (predicted PPMCT).

Results: In an analysis of 2,463 patients, the frequency of measured PPM (moderate: 27.0%; severe: 8.7%) was higher than the frequency of predicted PPMTHV (moderate: 11.3%; severe: 1.2%) or predicted PPMCT (moderate: 12.0%; severe: 0.1%). During a median follow-up of 429 days, 10-year mortality was comparable in patients with versus without measured PPM or predicted PPMCT. In contrast, patients with moderate predicted PPMTHV had a lower risk of 10-year all-cause mortality compared with those without PPM (adjusted hazard ratio: 0.73, 95% confidence interval: 0.55-0.96).

Conclusions: The use of predicted versus measured EOAi results in a lower estimate of PPM severity. We observed no increased risk of death in patients with PPM over a median follow-up time of 429 days. ClinicalTrials.gov: NCT01368250.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

aortic stenosisimaging modalitiesmsctothertavrtransthoracic echocardiogram
Read next article
A novel device for atrial septal defect occlusion (GORE CARDIOFORM)

Latest news